摘要
目的探讨三阴性乳腺癌患者应用多西赛他赛的药代动力学参数与疗效、不良反应的相关性。方法对接受多西他赛(75 mg·m^(-2))联合希罗达(1 250 mg·m^(-2))方案治疗的20例Ⅳ期三阴性乳腺癌患者进行多西他赛有限样本血药浓度检测,计算出血药浓度曲线下面积(AUC)和清除率(CL),并分析两者与疗效和不良反应的相关性。结果白细胞减少组、肝功能损伤组、疾病控制组的AUC分别高于无白细胞减少组、无肝功能损伤组、疾病进展组;白细胞减少组、肝功能损伤组、疾病控制组的CL分别低于无白细胞减少组、无肝功能损伤组和疾病进展组。但仅有无白细胞减少组AUC比较差异有统计学意义(P<0.05)。结论多西他赛用药过程中进行血药浓度监测,可以达到个体化用药的目的,有利于提高疗效,减轻不良反应。
Objective To evaluate the correlation between pharmacokinetic parameters and efficacy or toxicities of doeetaxel in the patients with breast cancer. Methods Twenty patients with stage IV triple negative breast cancer were treated with docetaxel ＋ xeloda in order to detect blood drug concentration, and the area under the curve of blood concentration of docetaxel （AUG） and clearance （CL）, and the correlation with efficacy and toxicities were compared. A limited sampling strategy w as used in this study. Results AUC in the leucopenia group, the liver damage group and the disease control group was higher than those in the no leukopenia group, the liver damage group and the no disease control group. CL in the leukopenia group,liver damage group and the disease control group was lower than those in the no leukopenia group, the liver damage group and the no disease control group. There was statistical difference in the AUC between the leucopenia group and the no leucopenia group（ P 〈 0.05 ）. Conclusion In order to improve the curative effect, reduce drugs, it is necessary for to conduct blood drug concentration moni- toring in clinical work, achieving the purpose of individualized medication.
出处
《肿瘤基础与临床》
2017年第4期319-322,共4页
journal of basic and clinical oncology
